A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This study consists of two phases: the first portion of the study is a Phase 1 dose
escalation study to determine the maximum tolerated dose and the dose limiting toxicities of
SB1518 when given as a single agent orally once daily in subjects with advanced myeloid
malignancies; the second portion of the study is a Phase 2 study to define the efficacy and
safety profile of single-agent SB1518 at the recommended dose in subjects with chronic
idiopathic myelofibrosis (CIMF).